Investigational Oral JAK Inhibitor Gets Breakthrough Tx Status for Alopecia Areata
The FDA has granted Breakthrough Therapy designation to CTP-543 (Concert Pharmaceuticals), an oral Janus kinase (JAK) inhibitor for alopecia areata.
Alopecia
Baricitinib Receives Breakthrough Therapy Status for Alopecia Areata
The FDA has granted Breakthrough Therapy designation to baricitinib (LY3009104; Lilly), an oral Janus Kinase (JAK) inhibitor, for the treatment of alopecia areata.
Finasteride Uses, Efficacy Examined in Female Patients
Off-label use has become more common in women for treatment of alopecia and hirsutism.
Oral JAK3 Inhibitor Granted Breakthrough Tx Designation for Alopecia Areata
PF-06651600 is an investigational oral Janus kinase 3 (JAK3) inhibitor that is being evaluated in a Phase 2 study which will assess the treatment based on changes from baseline in Severity of Alopecia Tool (SALT) score.
Adverse Effect of Osteoporosis Drug May Help Treat Hair Loss
Researchers found that a non-immunosuppressant drug originally designed to treat osteoporosis (WAY-316606) targeted the same mechanism by antagonizing SFRP1, and after treating hair follicles with WAY-316606 for 6 days, the authors found enhanced human hair growth.
Endocrine Therapy-Induced Alopecia Seen in Breast Cancer
“Endocrine therapies are associated with a pattern alopecia similar to androgenetic-type, consistent with the mechanism of action of causal agents,” the authors write.
Potential First-in-Class Treatment Fast-Tracked for Alopecia Areata
Currently, there are no FDA approved treatments for alopecia areata.
PRP Injections Promising for Female Pattern Hair Loss
Significant improvement in hair volume and quality in PRP-injected sites, plus patient satisfaction
